Supply and sale of Indian version of Gleevec imatinib price

型号：

伊马替尼

规格：

100mg*120粒/盒

有效期：

24个月

Treatment should be initiated initially by a physician experienced in treating chronic myelogenous leukemia. Approximately % of patients taking imatinib mesylate develop severe water retention (pleural effusion, edema, pulmonary edema, and ascites), so regular weight monitoring is recommended in case of unexpected rapid weight gain during treatment. , detailed examination should be carried out, and appropriate supportive treatment and treatment measures should be taken if necessary.
Water retention can aggravate or lead to heart failure. There is currently no experience in the clinical application of imatinib mesylate
in patients with severe heart failure (according to the New York Heart Association classification). Use this drug with caution in these patients.
Patients with liver failure) The amount of imatinib mesylate
may be increased. Patients with liver damage should use this drug with caution.
Long-term clinical data on the safety and effectiveness of this drug are limited.
Preclinical studies have shown that imatinib mesylate
does not easily pass through the blood-brain barrier. It has not been studied in humans.
)Imatinib mesylate
It is recommended to check the complete blood count every week in the first month of treatment, every week in the second month, and then as needed (such as every month) . If severe neutropenia or thrombocytopenia occurs, the dose should be adjusted.
Liver function (including transaminases, bilirubin and alkaline phosphatase) should be checked before starting treatment, and then checked monthly or based on clinical conditions, and the dose should be adjusted if necessary.
Effects on the abilities of the driver and machine operator There is no information on possible effects on the abilities of the driver or machine operator.
Trade name) Gleevec
Common name) Imatinib mesylate
English name
[Characteristics]
The contents of this product’s capsule are crystalline granular powder shape.
[Indications]
It is used to treat patients with malignant gastrointestinal stromal tumors that cannot be surgically resected or have metastasized in patients with chronic myelogenous leukemia in blast phase, accelerated phase or chronic phase after failure of interferon therapy.
[Usage and Dosage]
The recommended starting dose of imatinib mesylate for patients in the blast phase and accelerated phase of chronic myelogenous leukemia is/day. For patients in the chronic phase who have failed interferon therapy, and For patients with malignant gastrointestinal stromal tumors that cannot be surgically removed or have metastasized, the recommended dose is 1/day, which should be taken orally once a day. They should take the medicine with meals and drink a large glass of water. As long as it is effective, it should be continued.
【Drug Overdose】
There is little experience with overdose, and there are no reported cases of overdose. If overdose occurs, the patient should be closely observed and given appropriate supportive care.
[Storage/Validity Period]
Should be stored under the following conditions. Valid for years.
【Manufacturer】
India Pharmaceutical Co., Ltd.